Was cash paid for John T. Cahill’s new Colgate Palmolive (CL) share grant?

No cash was paid for the 2,075-share grant to John T. Cahill, as the transaction price per share is reported as $0.00. It represents an annual director stock grant under Colgate Palmolive’s incentive compensation plan rather than an open-market purchase.

Colgate director granted shares and options

COLGATE PALMOLIVE CO director John T. Cahill reported routine equity compensation awards.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

COLGATE PALMOLIVE CO director John T. Cahill reported routine equity compensation awards. On May 11, 2026, he received an annual director stock grant of 2,075 shares of common stock, increasing his directly held shares to 28,216.

He also received an annual director stock option grant for 2,424 shares of common stock at a conversion price of $86.74 per share, with options vesting in equal annual installments over three years beginning on the first anniversary of the grant date and expiring on May 11, 2034. Separately, 36,357 shares are reported as held indirectly through a trust, which includes 2,019 shares previously reported as directly owned.

Insider Trade Summary

Grant/Award: 4,499 shares

Grant/Award 3 txns

Insider CAHILL JOHN T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,424	$0.00	$0.00
Grant/Award	Common Stock	2,075	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 2,424 contracts (Direct); Common Stock — 28,216 shares (Direct); Common Stock — 36,357 shares (Indirect, By Trust)

Footnotes (4)

F1. Annual director stock grant under the issuer's incentive compensation plan.
F2. This amount includes 2,019 shares that were previously reported as directly beneficially owned.
F3. Annual director stock option grant under the issuer's incentive compensation plan.
F4. Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date.

Key Figures

Director stock grant: 2,075 shares Stock options granted: 2,424 options Option conversion price: $86.74 per share +4 more

7 metrics

Director stock grant 2,075 shares Annual director stock grant of common stock on May 11, 2026

Stock options granted 2,424 options Annual director stock option grant on May 11, 2026

Option conversion price $86.74 per share Stock Option (Right to Buy) for 2,424 shares

Option expiration May 11, 2034 Expiration date of stock options granted May 11, 2026

Direct holdings after grant 28,216 shares Total Colgate common shares held directly after grant

Indirect holdings by trust 36,357 shares Common shares held indirectly through a trust

Reclassified shares 2,019 shares Previously reported as directly owned, now included in trust holdings

Key Terms

Annual director stock grant, Stock Option (Right to Buy), incentive compensation plan, indirect ownership, +1 more

5 terms

Annual director stock grant financial

"Annual director stock grant under the issuer's incentive compensation plan."

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

incentive compensation plan financial

"under the issuer's incentive compensation plan."

An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.

indirect ownership financial

"ownership_type: indirect, nature_of_ownership: By Trust"

beneficially owned financial

"includes 2,019 shares that were previously reported as directly beneficially owned."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did John T. Cahill report at Colgate Palmolive (CL)?

John T. Cahill reported an annual director stock grant of 2,075 Colgate Palmolive common shares and an annual director stock option grant for 2,424 shares. Both awards were made under the company’s incentive compensation plan as non-cash equity compensation.

How many Colgate Palmolive (CL) shares does John T. Cahill hold after this Form 4?

After these awards, John T. Cahill holds 28,216 Colgate Palmolive shares directly and 36,357 shares indirectly through a trust. The indirect amount includes 2,019 shares that had previously been reported as directly beneficially owned.

What are the terms of John T. Cahill’s new Colgate Palmolive (CL) stock options?

Cahill received stock options covering 2,424 Colgate Palmolive shares at a conversion price of $86.74 per share. The options vest in equal annual installments over three years, starting on the first anniversary of the May 11, 2026 grant date, and expire May 11, 2034.

How are John T. Cahill’s indirect Colgate Palmolive (CL) holdings structured?

Cahill’s indirect holding of 36,357 Colgate Palmolive shares is reported as held "By Trust." A footnote states this amount includes 2,019 shares that had previously been reported as directly beneficially owned, reflecting a change in how those shares are categorized.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/13/2026 - 04:46 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAHILL JOHN T

(Last)

(First)

(Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/11/2026		A⁽¹⁾		2,075	A	$0.0000	28,216	D
Common Stock								36,357⁽²⁾	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$86.74	05/11/2026		A⁽³⁾		2,424		⁽⁴⁾	05/11/2034	Common Stock	2,424	$0.0000	2,424	D

Explanation of Responses:

1. Annual director stock grant under the issuer's incentive compensation plan.

2. This amount includes 2,019 shares that were previously reported as directly beneficially owned.

3. Annual director stock option grant under the issuer's incentive compensation plan.

4. Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date.

	/s/ Kristine Hutchinson, Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR